@article{oai:kanazawa-u.repo.nii.ac.jp:00043169,
 author = {泉, 浩二 and 重原, 一慶 and 野原, 隆弘 and 角野, 佳史 and 南條, 成輝 and 山田, 忠明 and 大坪, 公士郎 and 矢野, 聖二 and 溝上, 敦 and Izumi, Kouji and Shigehara, Kazuyoshi and Nohara, Takahiro and Narimoto, Kazutaka and Kadono, Yoshifumi and Nanjo, Shigeki and Yamada, Tadaaki and Ohtsubo, Koushiro and Yano, Seiji and Mizokami, Atsushi},
 issue = {3-4},
 journal = {Journal of Medical Investigation},
 month = {},
 note = {Recent studies reveal that hypogonadism with low serum androgen levels is associated with advanced cancer and induction of most cancer-related symptoms. We designed an ARTFORM study to evaluate the efficacy of androgen replacement therapy in male advanced cancer patients. The ARTFORM study is an investigator-initiated, randomised controlled trial comparing intramuscle injection of testosterone enanthate with non-ad-ministration in male advanced cancer patients with non-curative locally advanced or metastatic lesions. Serum total and free testosterone levels are measured and patients with low testosterone level are randomised. The primary endpoint is the difference in validated health-related quality of life questionnaires at week 12. Trial registration of the ARTFORM study is assigned to University hospital Medical Information Network, Center identifier UMIN 000010939. © 2017, University of Tokushima. All rights reserved., 金沢大学附属病院泌尿器科},
 pages = {202--204},
 title = {Androgen replacement therapy for cancer-related symptoms in male advanced cancer patients: Study protocol for a randomised prospective trial (ARTFORM study)},
 volume = {64},
 year = {2017}
}